Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capmatinib - Novartis Oncology

Next Previous
Drug Profile

Capmatinib - Novartis Oncology

Alternative Names: INC-280; INCB-028060; INCB-28060; TABRECTA; Tabrecta

Latest Information Update: 08 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Heterocyclic bicyclo compounds; Imidazoles; Quinolines; Small molecules; Triazines
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Glioblastoma; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Phase I/II Breast cancer; Colorectal cancer; Head and neck cancer
  • No development reported Triple negative breast cancer

Most Recent Events

  • 05 Jun 2026 Registered for Non-small cell lung cancer (Metastatic disease, Late-stage disease) in Australia (PO)
  • 22 May 2025 Novartis Pharmaceuticals completes phase II GeoMETry-C clinical trials in Non-small cell lung cancer (Monotherapy, Late-stage disease, Metastatic disease) in China (PO, Tablet) (NCT04677595)
  • 29 Nov 2024 Novartis Pharmaceuticals terminates phase-II clinical trials in Non-small cell lung cancer (Adjuvant therapy, Neoadjuvant therapy, Late-stage disease) in USA (PO) due to recruitment challenges (NCT04926831)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top